A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells
- 18 March 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 55 (11), 1367-1373
- https://doi.org/10.1007/s00262-006-0131-0
Abstract
Prostate cancer is the most commonly diagnosed form of cancer and the second leading cancer-related death among men in the Western civilization. Since no effective therapy exists for this tumor after progression beyond resectable boundaries, there is an urgent need for new treatment strategies. Prostate specific membrane antigen (PSMA) represents an excellent target on prostate cancer cells, and therefore specific immunotherapy may be a novel therapeutic option for the management of this tumor. We constructed a fully recombinant immunotoxin (A5-PE40) from a single-chain antibody fragment (scFv) against cell-adherent PSMA and a truncated form of Pseudomonas exotoxin A (PE40) lacking its natural binding domain Ia. The scFv A5 was obtained from a mAb elicited with native PSMA by phage display technology and direct selection on cells carrying the antigen. The bacterially expressed and purified immunotoxin A5-PE40 specifically binds to PSMA-positive prostate cancer cells and induces a 50% reduction of viability (IC50) at a concentration of 20 pM, while PSMA-negative cells remain unaffected. Due to its high and specific toxicity this recombinant immunotoxin is a promising candidate for therapeutic applications in patients with prostate cancer.Keywords
This publication has 16 references indexed in Scilit:
- Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidaseProceedings of the National Academy of Sciences, 2005
- Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigenThe Prostate, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane AntigenJournal of Urology, 2003
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003
- Anti‐tumor effects of toxins targeted to the prostate specific membrane antigenThe Prostate, 2002
- An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA’) is a potent immunotoxin against a Hodgkin-derived cell lineBritish Journal of Cancer, 1999
- High level production of soluble single chain antibodies in small-scale Escherichia coli culturesJournal of Immunological Methods, 1997
- Recombinant human monoclonal antibodiesCell Biochemistry and Biophysics, 1992
- Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell, 1987